Klaudia Syska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Klaudia Syska has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jakub Janczura
Faculty of Medicine, Jan Kochanowski University, Kielce, Poland
1 shared publication - Klaudia Nowak
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Maja Cudzik
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Maria Paluch
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication - Wiktoria Gawlikowska
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-10
From steatosis to cirrhosis: the role of obesity in the progression of liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), the most common subtype of steatotic liver disease (SLD), affects approximately 38% of the global adult population and is strongly linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Projections estimate its prevalence may exceed 55% by 2040. Obesity plays a central role in the progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Excess adiposity contributes to hepatic fat accumulation, systemic inflammation, insulin resistance, and activation of hepatic stellate cells. key mechanisms in liver injury and fibrogenesis. Diagnosis traditionally relied on liver biopsy, but noninvasive techniques, along with serum-based indices, are now commonly used. MASLD is associated with an increased risk of cardiovascular disease, chronic kidney disease, and endocrine disorders, particularly in obese individuals. Management is centered on weight reduction, which can reverse steatosis, resolve MASH, and regress fibrosis depending on the degree of weight loss. Recent therapeutic advances include the approval of resmetirom, a thyroid hormone receptor-β agonist, and promising results from glucagon-like peptide 1 (GLP-1) receptor agonists. Bariatric surgery offers significant benefits in selected patients, improving liver histology and associated metabolic parameters. Despite these developments, no universally accepted pharmacotherapy exists for MASLD. Future directions include expanding access to diagnostic tools, validating novel biomarkers, and implementing public health strategies targeting obesity to prevent progression to end-stage liver disease.
- 14 October 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-10
Open AccessFrom steatosis to cirrhosis: the role of obesity in the progression of liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), the most common subtype of steatotic liver disease (SLD), affects approximately 38% of the global adult population and is strongly linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Projections estimate its prevalence may exceed 55% by 2040. Obesity plays a central role in the progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Excess adiposity contributes to hepatic fat accumulation, systemic inflammation, insulin resistance, and activation of hepatic stellate cells. key mechanisms in liver injury and fibrogenesis. Diagnosis traditionally relied on liver biopsy, but noninvasive techniques, along with serum-based indices, are now commonly used. MASLD is associated with an increased risk of cardiovascular disease, chronic kidney disease, and endocrine disorders, particularly in obese individuals. Management is centered on weight reduction, which can reverse steatosis, resolve MASH, and regress fibrosis depending on the degree of weight loss. Recent therapeutic advances include the approval of resmetirom, a thyroid hormone receptor-β agonist, and promising results from glucagon-like peptide 1 (GLP-1) receptor agonists. Bariatric surgery offers significant benefits in selected patients, improving liver histology and associated metabolic parameters. Despite these developments, no universally accepted pharmacotherapy exists for MASLD. Future directions include expanding access to diagnostic tools, validating novel biomarkers, and implementing public health strategies targeting obesity to prevent progression to end-stage liver disease.